Modelling approach Sample Clauses

Modelling approach. The program structure is represented in Figure 1. Figure 1 – Code structure: 1) Main program, 2) Reactor model and 3) Model Parameters (based on [2]) As observed in Figure 1 (2-3) modelling of fluidized bed reactors involves an accurate coupling of several phenomena. Firstly, we have the model structure composed by a set of consistent differential balances (mass, energy and pressure) from which the state variables profiles are obtained (e.g. gas and solids composition, temperature, pressure). Then, in order to represent the system at the operating conditions under study these balances are coupled with relations with different degrees of complexity that give information regarding the thermo-chemical properties, geometry, physics and hydrodynamics of the system (the model parameters). The present model relies on the following assumptions:
Sample 1
AutoNDA by SimpleDocs
Modelling approach. The model will be developed in Microsoft Excel. Visual basic functionality will be incorporated to facilitate probabilistic sensitivity analyses. The model will adhere to the principles laid out in the CPHE Methods Manual (Chapter 6) and other best practice guidance for economic evaluation (e.g. Xxxxxxxx, Philips). The long-run model will be a time-dependent probabilistic calculation of the health outcomes and associated costs for specifiable cohorts of individuals. These cohort members will be followed individually over a specifiable number of years over which period their BMI will change according to the base-line rule that they maintain the same percentile for the appropriate, age-dependent, national BMI distribution. Limited sensitivity analysis may be carried out on the BMI-change assumption after discussion with NICE. In addition, outcomes should be reported using an NHS perspective, public sector perspective and broader societal perspective. Cost consequences should be from a Local Government perspective. Weight management interventions on cohorts, or subsets of cohorts, of individuals will be modelled as initial, time-dependent shifts in BMI followed by a probabilistic model of weight recovery or adherence to the weight management programmme. For each modelled individual a state vector will be maintained. The elements of this vector will include: age, gender, BMI, the probability of being alive, the probability of being in a number of BMI- related disease states, QALYs, and other lifestyle-weight management outcomes of interest. The timing of costs and benefits should be reported following receipt of the lifestyle weight management intervention across the lifetime as appropriate, to reflect the findings of the evidence reviews and discussions with NICE and the relevant Programme Development Group.
Sample 1
Modelling approach. The mass and energy balances of the reference cement kiln have been reproduced by Polimi starting from the detailed mass balance provided by VDZ. Mass and energy balances have been estimated by the proprietary code GS [GS] developed by the GECOS group of the Department of Energy of the Politecnico di Milano. The program has the capability of simulating complex energy processes by means of a modular structure. The GS process simulation model does not include any predictive model for the calculation of the cement kiln components. Therefore, parameters such as the efficiency of cyclones, the calcination efficiency in pre-calciner, the heat losses, etc. are provided as inputs to the GS code as they result from external models or from proper assumptions. The sub- processes of the cement kiln are therefore simulated by assembling a combination of elemental components like mixers, splitters, heat exchangers and chemical reactors. A very simple example regards the simulation of the last riser-cyclone stage of the preheating tower, conceptually represented in Figure 3.2. The riser-cyclone stage is simulated by using two mixers (A, D) and two splitters (B, C). The first mixer (A - riser) receives the fresh raw meal fed to the cement kiln (stream #0) and the gaseous stream coming from the previous preheater stage (#1), and releases a gas-solid mixture at the equilibrium temperature. The components B,C and D represents the cyclone: in B, the gaseous flow (#4) is separated from the solid particles (#3), in C a fraction of the solid stream is separated from the main flow to simulate the cyclone efficiency. The uncollected stream (#5) is then mixed in the last component of the stage (D), which releases the final gas-solid mixture (#7). The remaining solid stream is sent to the following preheating stage (components E, F, G, H). In each riser-cyclone stage, the riser (components A, E, I, etc…) can be also used for simulating reactions, as for example the decomposition of MgCO3 into MgO and XX0 (@000°X); in addition, this component is also exploited to set (as an input value) the heat losses associated with the preheating stage. Figure 3.2: Modular structure used for simulating the first three riser-cyclone stages of the preheating tower. Once the input file has been developed by assessing all the streams sequence and the related components layout, GS performs the iterative calculation of each component providing the overall mass and energy balances. Although the current G...
Sample 1
Modelling approach. The mass and energy balances have been estimated by use of Aspen Plus V8.8. An overview of the Aspen Plus set-up used to calculate the mass and energy balances is given in
Sample 1

Related to Modelling approach

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • STAGE If the is not satisfied with the decision of the Chair or designee or if a decision is not received within the specified time limits, the may apply to the Crown Employees Grievance Settlement Board for a hearing of the grievance within five (5) days of the date received the decision or within five (5) days of the expiration of the specified time limit for receiving a decision. An employee claiming has been dismissed without just cause shall be entitled to file a grievance commencing at STAGE provided does so within ten (10) days of the date of the dismissal. The Union shall have the right to lodge a grievance based on a difference arising directly with the Employer. However, such a grievance shall not include any matter upon which an employee is personally entitled to grieve. Such grievance shall first be presented, in writing, to the Employer within twenty (20) days of the circumstances giving rise to the grievance. A meeting between representatives of the Union and the Employer will be held within ten days of receipt of the grievance. The grievance shall be answered in writing by the Employer within ten days of such meeting, following which or failing settlement of the grievance, the Union may submit the grievance to the Crown Employees Grievance Settlement Board within a further period of ten days. The Employer shall have the right to lodge a grievance as defined above or relating to the conduct of the Union or any officer or representative of the Union or the conduct of the employee. Such grievance shall first be presented, in writing, to the Union within twenty (20) days of the circumstances giving rise to the grievance. A meeting between representatives of the Union and the Employer will be held within ten days of receipt of the grievance. The grievance shall be answered in writing by the Union within ten days of such meeting, following which or failing settlement of the grievance, the Employer may submit the grievance to the Crown Employees Grievance Settlement Board within a further period of ten days. The Crown Employees Grievance Settlement Board shall not be authorized to alter, modify or amend any part of this Agreement nor shall the Crown Employees Grievance Settlement Board give any decision inconsistent with the provisions of this Agreement. The determination of a grievance by the Crown Employees Grievance Settlement Board pursuant to the terms of this Agreement is final and binding upon the parties and the employees covered by this Agreement. At any STAGE of the Grievance Procedure, the time limits imposed upon either party may be extended, in writing, by mutual agreement. As an alternative to the procedures described at STAGE in Article the parties may choose to proceed with final disposition of a grievance by the use of Mediation/ Arbitration. This alternative shall be implemented within the provisions of Appendix of this Agreement and agreed as being in conformity with the provisions of Article of this Agreement. Where a grievance is not processed within the time allowed or has not been processed by the employee or the Union within the time prescribed it shall be deemed to have been withdrawn.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!